Clinical trial evaluates a combination therapy for metastatic clear cell renal carcinoma

Kidney cancer is the 6th most common cancer diagnosed in the United States with greater than 73,000 new cases seen each year. CCR investigators are interested in studying a combination immunotherapy for its most common subtype, clear cell renal carcinoma, using Avelumab and interleukin (IL)-15. Read more...

Stephen Oroszlan

In Memoriam: Stephen Oroszlan, Ph.D.

May 15, 2020

The Center for Cancer Research mourns the recent death of past colleague and friend Stephen Oroszlan. He was an esteemed member of the NCI community from 1976-1995 and served as a Scientist Emeritus since 1995.  Read more...

Eytan Ruppin

Eytan Ruppin quoted in New York Times story on treating COVID-19

May 15, 2020

The New York Times has reported on a new paper detailing drugs with the potential to treat COVID-19 by researchers from international institutions. Eytan Ruppin, Ph.D., Chief of the Cancer Data Science Laboratory, turned the computer network his lab uses toward analyzing some of the drugs that did best in the screening to predict which are likely to succeed in actual patients and in what combinations. Read more...

Ira Pastan

Ira Pastan selected as a 2020 Sammies finalist

May 4, 2020

Ira Pastan, M.D., Co-Chief of the Laboratory of Molecular Biology, has been selected as one of 27 Samuel J. Heyman Service to America Medal (Sammies) finalists. These finalists are outstanding federal employees who serve the public good and are addressing many of our country’s greatest challenges. Dr. Pastan is nominated for discovering a new class of drugs that can successfully treat a rare form of leukemia and hold promise to be effective therapies for pancreatic and lung cancer as well as mesothelioma. Read more...

John Schiller

John Schiller elected to the National Academy of Sciences

Apr 29, 2020

John T. Schiller, Ph.D., Deputy Chief of the Laboratory of Cellular Oncology, has been elected to the National Academy of Sciences for his distinguished and continuing achievements in original research. Dr. Schiller, in close partnership with Dr. Doug Lowy, has made fundamental contributions to our understanding of human papillomavirus (HPV) culminating in the development of the prophylactic vaccines Cervarix and Gardasil, which protect from HPV-related cancers, including cervical cancer. Read more...

CAR T-cell therapy

NCI initiative aims to boost CAR T-cell therapy clinical trials

Apr 23, 2020

Researchers at the Center for Cancer Research are part of a new NCI initiative to manufacture CAR T-cell therapies for clinical trials being conducted at multiple hospitals. Nirali N. Shah, M.D., Lasker Clinical Research Scholar in the Pediatric Oncology Branch, is a co-lead investigator on the first trial of this initiative that is testing a CAR T-cell therapy designed to target a protein on cancer cells called CD33 in children and young adults with advanced forms of acute myeloid leukemiaRead more...

Andrea Apolo

Andrea Apolo receives Arthur S. Flemming Award

Apr 21, 2020

Andrea B. Apolo, M.D., NIH Lasker Clinical Research Scholar in the Genitourinary Malignancies Branch, is a recipient of this year’s Arthur S. Flemming Award, which honors the accomplishments of mid-career federal employees. Dr. Apolo received the award for her work leading a clinical trial demonstrating that avelumab treatment led to prolonged survival in patients with refractory metastatic urothelial carcinoma. She then led the effort to get avelumab approved by the FDA for the treatment of bladder cancer. Read more...

William Dahut

Dr. William Dahut discusses coronavirus and cancer patients on Frankly Speaking about Cancer podcast

Apr 21, 2020

William L. Dahut, M.D., CCR Clinical Director, was a guest on the Frankly Speaking about Cancer podcast for their spotlight on coronavirus series. He addressed concerns from cancer patients and their caregivers and shared advice on what cancer patients can do to stay safe.  Read more...

Neurofibromatosis team and patient

The discovery of selumetinib for children with NF1

Apr 21, 2020

When Brigitte Widemann, M.D., Chief of the Pediatric Oncology Branch (POB), saw selumetinib shrinking the first child’s tumor, she couldn’t believe her eyes. Then, when she saw the second patient’s tumor shrinking, “I thought, oh my gosh, it’s working!” she recalls. Over 30 years of NCI-led and NCI-supported research culminated in clinical trials of selumetinib for kids with neurofibromatosis type 1 (NF1) and associated tumors called plexiform neurofibromas (PNs). With Food and Drug Administration (FDA) approval, selumetinib is now the first effective treatment for kids with PNs that can't be removed by surgery. Read more...

Mom and daughter

FDA approves first therapy for children with neurofibromatosis type 1

Apr 15, 2020

The Food and Drug Administration (FDA) has approved selumetinib (Koselugo) to treat children with neurofibromatosis type 1 (NF1) and tumors called plexiform neurofibromas. The approval was based on results from a clinical trial, designed and led by Brigitte Widemann, M.D., Chief of the Pediatric Oncology Branch (POB), and Andrea M. Gross, M.D., Assistant Research Physician in POB, that showed the drug shrank neurofibromas in 70 percent of patients. For many children in the trial, treatment with selumetinib also had clinical benefit, improving their pain, function and quality of life. Read more...

diffuse large B-cell lymphoma

New genetic analysis will help researchers understand how diffuse large B-cell lymphoma subtypes respond to experimental therapies

Apr 14, 2020

By looking for about 100 potential genetic abnormalities in the DNA of certain lymphomas, researchers can now assign individual cases of DLBCL to one of seven subtypes. The new classification system will better equip researchers to recognize the impact of experimental therapies on subsets of patients whose cancers share key clinical and biological features.  Read more...

Pages